Alligator Bioscience logo

Alligator Bioscience Investor Relations Material

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc

Upcoming events for

Q4 20222023-02-10
Q1 20232023-04-26

Latest company events

Ticker symbol

ATORX

Country

Sweden

Dig deeper into the Alligator Bioscience fundamentals on Quartr.

  • Conference calls from all over the world
  • Search for anything across all transcripts
  • Consensus estimates
  • Comprehensive financial data
  • Read the transcripts or scroll the deck
  • Slide decks and earnings reports
App store link
Android play link
Quartr app screenshot